Research
BPC-157: what the evidence shows
BPC-157 is the most searched compound in this market and one of the least tested in people. The rodent literature is large and genuinely interesting. The human record is four registered studies with no results posted and a regulator that could not find a single study giving it by the routes it is sold in.
- The BPC-157 board ranks no provider, and carries the dated regulatory position that explains why.
- Set against another compound on the same evidence standard: BPC-157 vs KPV and BPC-157 vs TB-500.
What BPC-157 is
BPC-157 is a chain of fifteen amino acids. It is a fragment of a larger protein called Body Protection Compound, which was originally isolated from human gastric juice and first described in the literature in 1993.
The full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is sold as a free base and as an acetate salt, and those two are different substances with different chemical identifiers, even though sellers and study authors often use one name for both.
No approved product containing BPC-157 exists in any country. It has no monograph in the European, Japanese or International Pharmacopeias. Everything sold under the name is either a compounded preparation or a research-chemical vial.
The use regulators examined is not the use it is sold for
BPC-157 is marketed for tendon and ligament recovery, joint pain, and gut repair. That is what the search traffic is about and what the sales copy promises.
When the compound came before the FDA Pharmacy Compounding Advisory Committee in July 2026, the use under evaluation was ulcerative colitis. That is the indication the nominators put forward, and it is the one the agency reviewed the evidence against.
The gap matters. A regulator assessing a compound for ulcerative colitis is not testing the tendon claim, the joint claim or the recovery claim. Nothing in that review supports them, and nothing in it rules them out either. They were simply never on the table.
What a search of the published record actually returns
Searching PubMed in September 2026 for BPC-157 in a title or abstract returns 227 records. Fifty-one of those carry the tag for human subjects. None of them carries the tag for a randomized controlled trial.
That zero needs a control beside it or it means nothing. Run through the identical filter in the same session, aspirin returns 5,085 randomized controlled trials and semaglutide returns 303. A deliberately nonsense search term returns zero. The filter works, and the zero for BPC-157 is a real zero rather than a broken query.
One more check is worth stating plainly, because a widely used but invalid version of that filter silently returns zero for every term including aspirin. Run in the same session, that invalid form returned zero for aspirin too, which is how a broken ruler gets caught before it is trusted.
The FDA review found no human studies by the routes it is sold in
The agency's own briefing document is blunter than any summary of it. It states that FDA found no studies administering BPC-157 to humans by the oral, subcutaneous, nasal or transdermal route.
Two studies gave it as a rectal enema, to healthy subjects or to subjects with ulcerative colitis, for a maximum of two weeks. No serious adverse events were reported, and the reviewers noted that the authors provided limited information about safety and safety monitoring.
A single small trial has looked at BPC-157 in ulcerative colitis. FDA described its interpretation as limited by the lack of detail in a meeting abstract and by the exploratory nature of the study.
Nearly every vial sold today is sold for injection. The published human record, such as it is, is about a rectal preparation in a bowel condition.
The animal work is real, and it stops short of a mechanism
Rodent studies have reported that BPC-157 prevents colonic fistulas and reduces gastrointestinal and hepatic injury caused by various challenges. That body of work is substantial and it is why the compound attracted attention in the first place.
FDA's reviewers gave a specific reason for not carrying it forward. Dose-response relationships have not been established. The molecular targets have not been identified. The mechanisms of action remain poorly understood.
A finding without a dose-response curve and without a known target is a starting point for research rather than a basis for a treatment. Marketing copy routinely presents the rodent results as though the clinical step had already been taken.
What is known about safety, and what is simply unknown
Being under-studied is not the same as being proven harmful, and the two get conflated in both directions. What follows is the difference.
FDA reported adverse events in its post-market database associated with BPC-157: injection site reaction, shortness of breath, diffuse hyperpigmentation and gingival darkening. The agency noted it is unclear whether those events were attributable to BPC-157, because such reports carry limited information and involve other medications.
The structural concern is separate from any of those reports. A fifteen-amino-acid peptide given by injection can provoke an immune response, and that risk rises with aggregation and with peptide-related impurities. FDA found no information about BPC-157 suggesting it does not carry that risk. There is also no data on how it behaves in the human body over time.
Ulcerative colitis is a chronic condition that can need years of treatment, and several approved drugs already treat it. That combination weighed against the compound in the agency's reasoning.
Four registered trials, none with results
A registry search in September 2026 returns four studies naming BPC-157 as an intervention on ClinicalTrials.gov. None has posted results.
One is a phase 2 trial in acute hamstring strain that began recruiting in early 2026. One is a phase 1 study in rotator cuff repair recovery listed as not yet recruiting. One is a completed study of peptide gummies with no results filed. One is a phase 1 safety and pharmacokinetics trial from 2015 whose status is listed as unknown.
The control matters here too. Through the identical registry search in the same session, semaglutide returns 748 studies and aspirin returns 2,181. A nonsense term returns zero. The registry is not blind to this compound. Four studies is what exists.
Registered is not published, and recruiting is not finished. A trial that has begun tells you a question is being asked, not that it has been answered.
Where this leaves a buyer
Anyone selling BPC-157 for human use in the United States is selling ahead of the rule rather than under it. The board for this compound carries the dated regulatory note and the current status.
The evidence grade here is the lowest of the three tiers used on this site: no controlled human evidence. That is a description of the published record, not a verdict on the molecule.
BPC-157 also appears on the World Anti-Doping Agency's prohibited list, under its non-approved substances section. That matters to anyone subject to drug testing in sport, whatever they conclude about the evidence.
Key takeaways
- BPC-157 is a fifteen-amino-acid fragment of a protein first isolated from gastric juice and described in 1993.
- No approved product containing it exists in any country, and it has no pharmacopeial monograph.
- FDA evaluated it for ulcerative colitis, not for the tendon, joint or recovery uses it is sold for.
- A September 2026 PubMed search returned 227 records and zero randomized controlled trials, with aspirin returning 5,085 through the same filter.
- FDA found no studies giving BPC-157 to humans by the oral, subcutaneous, nasal or transdermal route.
- Four studies are registered on ClinicalTrials.gov and none has posted results.
Frequently asked questions
Are there human studies on BPC-157?
A few, and none of them tests the way it is sold. FDA's July 2026 briefing document states the agency found no studies administering BPC-157 to humans by the oral, subcutaneous, nasal or transdermal route. Two studies used a rectal enema for up to two weeks. One small exploratory trial in ulcerative colitis exists, reported in a meeting abstract with too little detail to interpret. Four studies are registered on ClinicalTrials.gov and none has posted results.
Why is BPC-157 so widely sold if the evidence is this thin?
Because search demand for it is enormous and the compound is cheap to synthesize. The rodent literature is large enough to fill a page of citations, which makes the sales copy look well supported to anyone who does not check whether those studies were in people. Regulatory pressure has kept most compliant telehealth companies out of the category, so much of what is available moves through research-chemical channels instead.
Is BPC-157 legal to buy?
Vials labeled for research use only are sold as laboratory chemicals rather than medicines, which is how they reach consumers without a prescription. Compounding BPC-157 into a medication for a patient is a different question, and the answer turns on whether the substance may lawfully be used in compounding at all. The BPC-157 board carries that status with the date it was last checked.
Does the animal research count as evidence?
It counts as evidence that something happens in rodents. It does not carry across to people on its own. FDA gave concrete reasons why this particular body of work does not: no established dose-response relationship, no identified molecular target, and mechanisms that remain poorly understood. Most compounds that work in rodent injury models never work in humans, which is why the clinical step exists.
What would move BPC-157 out of the lowest evidence tier?
Controlled human trials that administer it by a route people actually use, in a condition people actually take it for, with results published rather than only registered. Two of the four registered studies could produce exactly that. Until results are posted and reviewed, the grade describes what has been measured, which is very little.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- FDA Briefing Document for BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, April 2026
- Meeting of the Pharmacy Compounding Advisory Committee — agenda and uses evaluated — U.S. Food and Drug Administration, July 2026
- PubMed literature census for BPC-157, run with a positive control through the same filter — National Library of Medicine, September 2026
- Registered study census for BPC-157, run with a positive control through the same query — ClinicalTrials.gov, National Library of Medicine, September 2026